Literature DB >> 23753022

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.

Franck E Nicolini, H Jean Khoury, Luke Akard, Delphine Rea, Hagop Kantarjian, Michele Baccarani, Janis Leonoudakis, Adam Craig, Annie-Claude Benichou, Jorge Cortes.   

Abstract

Entities:  

Keywords:  advanced chronic myeloid leukemia; dasatinib; homoharringtonine; imatinib; nilotinib; omacetaxine; tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2013        PMID： 23753022      PMCID： PMC3696599          DOI： 10.3324/haematol.2012.083006

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Authors:  Susan Branford; Zbigniew Rudzki; Sonya Walsh; Ian Parkinson; Andrew Grigg; Jeff Szer; Kerry Taylor; Richard Herrmann; John F Seymour; Chris Arthur; David Joske; Kevin Lynch; Tim Hughes
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

2.  Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Gianantonio Rosti; Fausto Castagnetti; Angela Poerio; Ilaria Iacobucci; Marilina Amabile; Elisabetta Abruzzese; Ester Orlandi; Franca Radaelli; Fabrizio Ciccone; Mario Tiribelli; Roberto di Lorenzo; Clementina Caracciolo; Barbara Izzo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; Giovanni Martinelli
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

3.  Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation.

Authors:  R M Tujebajeva; D M Graifer; G G Karpova; N A Ajtkhozhina
Journal:  FEBS Lett       Date:  1989-11-06       Impact factor: 4.124

4.  Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells.

Authors:  E K Allan; T L Holyoake; A R Craig; H G Jørgensen
Journal:  Leukemia       Date:  2011-04-05       Impact factor: 11.528

5.  A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.

Authors:  Rong Chen; Varsha Gandhi; William Plunkett
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

6.  Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells.

Authors:  Ruoping Tang; Anne-Marie Faussat; Patricia Majdak; Christophe Marzac; Sabine Dubrulle; Zora Marjanovic; Ollivier Legrand; Jean-Pierre Marie
Journal:  Mol Cancer Ther       Date:  2006-03       Impact factor: 6.261

7.  Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin.

Authors:  Junya Kuroda; Yuri Kamitsuji; Shinya Kimura; Eishi Ashihara; Eri Kawata; Yoko Nakagawa; Miki Takeuichi; Yoshihide Murotani; Asumi Yokota; Ruriko Tanaka; Michael Andreeff; Masafumi Taniwaki; Taira Maekawa
Journal:  Int J Hematol       Date:  2008-04-17       Impact factor: 2.490

8.  Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.

Authors:  Jorge E Cortes; Franck E Nicolini; Meir Wetzler; Jeffrey H Lipton; Luke Akard; Adam Craig; Nisha Nanda; Annie-Claude Benichou; Janis Leonoudakis; H Jean Khoury; Andreas Hochhaus; Michele Baccarani; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-17

9.  Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.

Authors:  Y Chen; Y Hu; S Michaels; D Segal; D Brown; S Li
Journal:  Leukemia       Date:  2009-03-26       Impact factor: 11.528
  9 in total
  11 in total

Review 1.  Novel drugs for older patients with acute myeloid leukemia.

Authors:  G Montalban-Bravo; G Garcia-Manero
Journal:  Leukemia       Date:  2014-08-21       Impact factor: 11.528

2.  Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.

Authors:  Jorge E Cortes; Hagop M Kantarjian; Delphine Rea; Meir Wetzler; Jeffrey H Lipton; Luke Akard; H Jean Khoury; Mauricette Michallet; Agnès Guerci-Bresler; Charles Chuah; Andrzej Hellmann; Raghunadharao Digumarti; Purvish M Parikh; Laurence Legros; Krzysztof Warzocha; Michele Baccarani; Elizabeth Li; Mihaela Munteanu; Franck E Nicolini
Journal:  Cancer       Date:  2015-01-13       Impact factor: 6.860

Review 3.  Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.

Authors:  Uday Deotare; Dennis Dong Hwan Kim; Jeffrey H Lipton
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

4.  Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.

Authors:  Luke Akard; Hagop M Kantarjian; Franck E Nicolini; Meir Wetzler; Jeffrey H Lipton; Michele Baccarani; H Jean Khoury; Sandra Kurtin; Elizabeth Li; Mihaela Munteanu; Jorge Cortes
Journal:  Leuk Lymphoma       Date:  2015-10-05

Review 5.  Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.

Authors:  Kodappully S Siveen; Kirti S Prabhu; Iman W Achkar; Shilpa Kuttikrishnan; Sunitha Shyam; Abdul Q Khan; Maysaloun Merhi; Said Dermime; Shahab Uddin
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

6.  Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology.

Authors:  Vlad Moisoiu; Patric Teodorescu; Lorand Parajdi; Sergiu Pasca; Mihnea Zdrenghea; Delia Dima; Radu Precup; Ciprian Tomuleasa; Simona Soverini
Journal:  Front Oncol       Date:  2019-09-23       Impact factor: 6.244

7.  Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma.

Authors:  Ling Li; Gilad Halpert; Michael G Lerner; Haijie Hu; Peter Dimitrion; Matthew J Weiss; Jin He; Benjamin Philosophe; Richard Burkhart; William R Burns; Russell N Wesson; Andrew MacGregor Cameron; Christopher L Wolfgang; Christos Georgiades; Satomi Kawamoto; Nilofer S Azad; Mark Yarchoan; Stephen J Meltzer; Kiyoko Oshima; Laura M Ensign; Joel S Bader; Florin M Selaru
Journal:  JCI Insight       Date:  2021-06-22

Review 8.  Potential Antiviral Action of Alkaloids.

Authors:  Frage L Abookleesh; Bader S Al-Anzi; Aman Ullah
Journal:  Molecules       Date:  2022-01-28       Impact factor: 4.411

9.  How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice.

Authors:  Guru Subramanian Guru Murthy
Journal:  Blood Lymphat Cancer       Date:  2022-03-19

Review 10.  Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.

Authors:  Yaoyu Chen; Shaoguang Li
Journal:  Onco Targets Ther       Date:  2014-01-31       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.